Related Experiment Videos

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

Jean-Charles Fruchart1, Frank M Sacks, Michel P Hermans

  • 1Inserm UR 545, Universite Lille 2, Lille, France. Jean-Charles.Fruchart@pasteur-lille.fr

Diabetes & Vascular Disease Research
|October 30, 2008
PubMed

Insights

Patients with dyslipidaemia face high residual vascular risk despite standard care. Addressing atherogenic dyslipidaemia through lifestyle changes and pharmacotherapy, like adding niacin or fibrates to statins, is crucial for reducing this risk.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Dyslipidaemic patients often have high residual risk of vascular events, even with current treatments for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycaemia.
  • Atherogenic dyslipidaemia, characterized by elevated triglycerides and low high-density lipoprotein (HDL) cholesterol, is prevalent in patients with cardiovascular disease, type 2 diabetes, obesity, or metabolic syndrome, contributing to residual vascular risk.
  • The Residual Risk Reduction Initiative (R3I) was formed to address this significant clinical challenge.

Purpose of the Study:

  • To present evidence that atherogenic dyslipidaemia contributes to residual macrovascular and microvascular risk.
  • To recommend therapeutic interventions for reducing residual vascular risk in dyslipidaemic patients, based on expert consensus and scientific evidence.
  • To emphasize the need for additional management strategies beyond current standards of care.

Main Methods:

  • Review of existing evidence on atherogenic dyslipidaemia and residual vascular risk.
  • Expert consensus development within the Residual Risk Reduction Initiative (R3I).
  • Evaluation of lifestyle modifications and pharmacotherapies, including niacin, fibrates, and omega-3 fatty acids, in conjunction with statin therapy.

Main Results:

  • Atherogenic dyslipidaemia is a common contributor to residual vascular risk in patients with cardiovascular disease, type 2 diabetes, obesity, or metabolic syndrome.
  • Lifestyle modification is a foundational element in managing dyslipidaemia.
  • Combination therapy, such as adding niacin, fibrates, or omega-3 fatty acids to statins, improves lipid profiles and is being evaluated for enhanced clinical outcomes.

Conclusions:

  • Current standards of care do not fully mitigate residual vascular risk in many dyslipidaemic patients.
  • Addressing atherogenic dyslipidaemia through lifestyle changes and/or pharmacotherapy is essential for reducing residual vascular risk.
  • Further outcomes studies are needed to confirm the clinical benefits of add-on therapies to statins for reducing vascular events.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...